This conversation focuses on why use of NITs is such a pivotal issue for MASH treatment and drug adoption, particularly if, as expected, the first MASH drug is approved this month.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
From 2022: Chris Estes, then from the Center for Disease Analysis Foundation, and Alina Allen from the Mayo Clinic join the Surfers to discuss the creation of a 15-country epidemiology model for MASLD/NAFLD and MASH/NASH and what it tells us about the future path of the disease, and specifically treatment of advanced fibrosis.
As the episode comes to an end, the group winds up focusing on the need for better, more frequent MASH education as a pivotal need if we are to flatten the growth curve of the MASLD pandemic. In the process, the discussion returns to the risk for women and the important role they can play.
Zobair Younossi joins the Surfers to discuss cost and cost effectiveness, including both how it is measured and how stakeholders might think about it, in the context of the MASLD disease burden.
Zobair Younossi discusses the disease burden of MASLD as characterized in his recent publication “Understanding the Burden of Fatty Liver Disease: Time for Action”
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.
Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
